Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.
- 1Department of Paediatrics, Mangla Hospital Research Centre, Bijnor, Uttar Pradesh, India.
- 2Department of Paediatrics, Kumar Child Clinic, New Delhi, India.
Abstract
India's approval of TAK-003 (Qdenga) on July 20, 2026, marks a defining moment in dengue prevention, yet four-serotype complexity demands a calibrated rather than uniform strategy. Built on a live-attenuated DENV-2 backbone, TAK-003 generates lower type-specific neutralising antibody titres - most critically against DENV-3 - an imbalance compounded by original antigenic sin, which may further limit cellular priming against DENV-3 and DENV-4. India's epidemiology amplifies these concerns: DENV-3 accounted for nearly 80% of typed cases in Bengaluru in 2024 - a regional signal, though serotype dominance varies across States - and large seronegative peri-urban populations remain vulnerable. NIH TV003-derived vaccines, including India's DengiAll in Phase 3, incorporate attenuated strains of all four serotypes, offering potentially broader immunity. TAK-003's demonstrated efficacy against severe dengue and hospitalisation - including in seronegative participants - makes it a valuable first-line tool. We argue for a phased, serotype-informed strategy: deploy TAK-003 now, while building surveillance capacity for vaccines with potentially broader serotype coverage.
Related
- Association of dengue severity with the serotype of infection: a systematic review and meta-analysis
- Serotype-structured force of infection for optimizing dengue vaccine trial design
- Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016–2023: A modelling study of case-notification data
- Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis.
- Early warning of serotype replacement, spatial risk redistribution, and shifting clinical phenotypes: Insights from the 2023–2025 dengue outbreak in Meta, Colombia
BibTeX
@article{vashishtha2026dengue,
title = {{Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.}},
author = {Vipin M Vashishtha and Puneet Kumar},
journal = {The Indian journal of medical research},
year = {2026},
month = aug,
doi = {10.25259/ijmr_1987_2026},
url = {https://europepmc.org/article/MED/42851221},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Dengue vaccines and serotype complexity: Why India needs a calibrated strategy.
AU - Vipin M Vashishtha
AU - Puneet Kumar
PY - 2026
DA - 2026/08/01
JO - The Indian journal of medical research
DO - 10.25259/ijmr_1987_2026
UR - https://europepmc.org/article/MED/42851221
AB - India's approval of TAK-003 (Qdenga) on July 20, 2026, marks a defining moment in dengue prevention, yet four-serotype complexity demands a calibrated rather than uniform strategy. Built on a live-attenuated DENV-2 backbone, TAK-003 generates lower type-specific neutralising antibody titres - most critically against DENV-3 - an imbalance compounded by original antigenic sin, which may further limit cellular priming against DENV-3 and DENV-4. India's epidemiology amplifies these concerns: DENV-3 accounted for nearly 80% of typed cases in Bengaluru in 2024 - a regional signal, though serotype dominance varies across States - and large seronegative peri-urban populations remain vulnerable. NIH TV003-derived vaccines, including India's DengiAll in Phase 3, incorporate attenuated strains of all four serotypes, offering potentially broader immunity. TAK-003's demonstrated efficacy against severe dengue and hospitalisation - including in seronegative participants - makes it a valuable first-line tool. We argue for a phased, serotype-informed strategy: deploy TAK-003 now, while building surveillance capacity for vaccines with potentially broader serotype coverage.
SN - 0971-5916
ER -